Abortion Pill Rules Unlikely to Change Before 2027 as Florida's Mifepristone Lawsuit Waits

Federal rules that let doctors prescribe the abortion pill mifepristone by telehealth and send it by mail are unlikely to change before next year, after the Food and Drug Administration told a federal court that its safety review of the drug will run into 2027. The timeline matters directly for Florida, which is one of two states suing the FDA to undo the drug's approval, and where thousands of residents each year receive the pills by mail from providers in other states despite Florida's six-week abortion ban.

The FDA's update came late Wednesday, Oct. 7, in a court-ordered status report. The agency said it expects to finish a safety study of mifepristone by mid-December and to issue a report on the findings no later than March 2027. Only after that will it decide whether to impose new restrictions or other changes on how the drug is prescribed and dispensed.

What the FDA told the court

The report was filed in Louisiana v. FDA, a separate lawsuit in which Louisiana argues that mailing mifepristone undermines its abortion ban. In it, the agency said it is comparing the safety record of medication abortion with that of surgical abortion, using data from inside and outside its Sentinel monitoring system, and is reviewing the drug's Risk Evaluation and Mitigation Strategy, including its 2023 decision to permanently allow telehealth prescribing and mail delivery. The Justice Department said the FDA would carry out any changes through its established processes.

Health and Human Services Secretary Robert F. Kennedy Jr. announced the review after anti-abortion groups pressed the FDA to reverse the telehealth rule. More than a year later, those groups are angry about the pace. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, called the update "alarming." Americans United for Life said the movement is prepared to reject a review it considers methodologically flawed. The FDA, which first approved mifepristone in 2000, has repeatedly reaffirmed its safety and effectiveness since.

Mary Ziegler, a law professor at the University of California, Davis, told States Newsroom the administration has held off on new restrictions mainly because Republicans see them as politically dangerous, and that the review is unlikely to settle the fight over one of the most studied and politicized drugs in the country. The timeline also tracks reporting that the administration intends to push contentious abortion decisions past the Nov. 3 midterm elections.

Florida's lawsuit, on hold until December

Florida Attorney General James Uthmeier and Texas Attorney General Ken Paxton filed their lawsuit in December 2025 in federal court in Wichita Falls, Texas. It asks the court to declare the FDA's original 2000 approval of mifepristone improper and to throw out a string of later decisions, among them a 2016 change that extended use from 49 to 70 days of pregnancy and allowed non-physicians to dispense the drug, and the 2021 and 2023 decisions that dropped the in-person dispensing requirement and allowed shipping. The states argue those actions were arbitrary and capricious under the Administrative Procedure Act and that the 1873 Comstock Act bars mailing abortion drugs.

On Aug. 30, Chief U.S. District Judge Reed O'Connor granted the Justice Department's request to pause the case until Dec. 1 or until the FDA finishes its safety review, whichever comes first. Texas and Florida agreed to the pause. In the same order, O'Connor refused a request from generic manufacturer GenBioPro and Danco Laboratories, which makes the brand-name drug, to dismiss the case. Because the FDA now says its report will not come until as late as March, the Dec. 1 date is the one that controls, unless the court extends the stay.

Florida's role in the litigation goes back further. In 2025, Uthmeier and Paxton tried to join a case brought by Missouri, Kansas and Idaho in the same Texas court, a move aimed at a venue problem since none of those states is in Texas. Explaining the effort in September 2025, Uthmeier said medications sent into Florida from out of state "can get into the hands of minors," and that the state believes the drug is dangerous. He was also one of 16 Republican attorneys general who asked Congress to consider overriding the shield laws that protect out-of-state prescribers.

How the pills reach Floridians now

Florida's Heartbeat Protection Act, passed in 2023, took effect May 1, 2024, after the Florida Supreme Court upheld the state's earlier 15-week law. It bans most abortions after six weeks of pregnancy, prohibits Florida physicians from using telehealth to perform abortions and requires abortion medications to be dispensed in person.

Those state rules do not reach doctors licensed in states with shield laws, which protect clinicians who prescribe to patients in states with bans. The #WeCount study by the Society of Family Planning estimated that 13,380 abortions were provided to patients in Florida under shield laws in 2024. Florida's own court filing cited 10,290 telehealth abortions in Florida from May through December 2024. Nationally, WeCount found telehealth accounted for 29% of abortions by the end of 2025, and shield-law providers were serving about 14,870 patients a month by December 2025.

Florida voters weighed in on the broader question in November 2024. Amendment 4, which would have protected abortion access until viability, won about 57% of the vote but fell short of the 60% that Florida requires for a constitutional amendment. The six-week law remained in place.

Where the other cases stand

The Louisiana case has already reached the U.S. Supreme Court once. On May 1, a panel of the 5th U.S. Circuit Court of Appeals reinstated the in-person dispensing requirement nationwide. On May 14, the Supreme Court stayed that order while the litigation continues, with Justices Samuel Alito and Clarence Thomas dissenting, leaving mail and pharmacy access in place. The appeal is back before the 5th Circuit, where a three-judge panel last month questioned whether Louisiana has standing. Because of the Supreme Court's stay, a 5th Circuit ruling would not immediately change access.

The key dates ahead are below.

What it means for Florida patients

For now, nothing changes. Mifepristone remains approved, and the federal rules allowing telehealth prescribing and mail delivery stay in effect nationwide. In Florida, the six-week ban and the state's in-person and telehealth restrictions also stay in effect, and the gap between those state rules and out-of-state shield-law prescribers remains the central tension behind Florida's lawsuit.

If the FDA ultimately restricts telehealth prescribing or restores in-person dispensing, it would sharply limit the mail-order route many Floridians now use. If the Texas court eventually sides with Florida and Texas on the 2000 approval, the effect could reach patients nationwide, including in states where abortion is legal.

What's next

The first marker is Dec. 1, when the stay in the Florida and Texas case expires unless the Justice Department asks for, and O'Connor grants, more time to wait on the FDA. Given the agency's new timeline, another request for delay is possible. After that, the FDA's report, due by March 2027, will set up the agency's decision on whether to rewrite the drug's safety rules, a decision Florida's attorney general and national anti-abortion groups have been pressing for, and one that abortion rights advocates are preparing to fight.